Home›Calculators›Health›DAPT Calculator

DAPT Calculator

Health

Calculate the DAPT score to estimate whether prolonged dual antiplatelet therapy after coronary stenting favors more ischemic benefit than added bleeding risk.

Age

Current Smoker

Diabetes Mellitus

MI at Presentation

Prior PCI or Prior MI

Stent Diameter Under 3mm

CHF or LVEF Under 30%

Saphenous Vein Graft PCI

Paclitaxel-Eluting Stent

DAPT Score

0

Risk-Benefit Assessment

—

Not a substitute for clinical judgment. Decisions about extending or stopping dual antiplatelet therapy directly affect bleeding and clotting risk — this score must never be used to change medication without a qualified cardiologist's guidance.

What is a DAPT Score?

The DAPT Calculator computes the DAPT score, a validated clinical tool for estimating whether prolonging dual antiplatelet therapy (DAPT) beyond the standard 12 months after coronary stent placement is likely to do more good than harm. The score sums points across nine factors — age, smoking, diabetes, MI at presentation, prior PCI or MI, small stent diameter, CHF or low ejection fraction, saphenous vein graft PCI, and paclitaxel-eluting stent type — with age being the only factor that subtracts points.

Select the applicable options below to see your total score and whether it favors prolonged or standard-duration therapy. For a related coronary risk tool used earlier in the care pathway, see the GRACE Calculator; for stroke risk in atrial fibrillation, see the CHA2DS2-VASc Calculator.

How to use this DAPT Score calculator

  1. Select your Age band — under 65, 65 to 74, or 75 or older.
  2. Select Yes or No for Current Smoker.
  3. Select Yes or No for Diabetes Mellitus.
  4. Select Yes or No for MI at Presentation.
  5. Select Yes or No for Prior PCI or Prior MI.
  6. Select Yes or No for Stent Diameter Under 3mm.
  7. Select Yes or No for CHF or LVEF Under 30%.
  8. Select Yes or No for Saphenous Vein Graft PCI.
  9. Select Yes or No for Paclitaxel-Eluting Stent.
  10. Review your DAPT Score and Risk-Benefit Assessment, and discuss the result with your cardiologist before your dual antiplatelet therapy duration decision.

Formula & Methodology

The DAPT score sums the following points:

- Age under 65: 0 points · 65 to 74: −1 point · 75 or older: −2 points
- Current smoker: +1 point
- Diabetes mellitus: +1 point
- MI at presentation: +1 point
- Prior PCI or prior MI: +1 point
- Stent diameter under 3mm: +1 point
- CHF or LVEF under 30%: +2 points
- Saphenous vein graft PCI: +2 points
- Paclitaxel-eluting stent: +1 point

Total score = sum of all applicable points (range −2 to 10). A score ≥2 is favorable for prolonged DAPT; a score <2 is unfavorable.

Worked example: A 58-year-old current smoker with diabetes and a saphenous vein graft PCI scores: Age (0 points) + Smoker (1 point) + Diabetes (1 point) + SVG PCI (2 points) = 4 points total, a favorable score suggesting prolonged dual antiplatelet therapy is likely to provide net benefit, per the original DAPT Study derivation (Yeh RW, et al. JAMA. 2016).

Frequently Asked Questions

The DAPT score predicts whether extending dual antiplatelet therapy beyond the standard 12 months after coronary stent placement is likely to provide more benefit (reducing stent thrombosis and heart attack) than harm (increased bleeding risk). It was derived and validated in the DAPT Study, a large randomized trial of prolonged versus standard-duration therapy.
A total score of 2 or higher is considered favorable, meaning the modeled ischemic-event reduction from continuing dual antiplatelet therapy beyond 12 months is likely to outweigh the added bleeding risk in patients like the DAPT Study population. A score below 2 suggests standard-duration therapy is generally preferred.
Older age is strongly associated with higher bleeding risk on prolonged antiplatelet therapy, so the DAPT score subtracts points for age 65 and older to reflect that the balance shifts toward bleeding risk as patients age. This is the only factor in the score that reduces the total rather than increasing it.
The DAPT score defines a small stent as one with a diameter under 3mm, which adds 1 point because smaller-diameter stents carry a somewhat higher risk of stent thrombosis. Your interventional cardiologist's procedure report will list the exact stent diameter used.
Both factors are weighted more heavily than the other single-point items because saphenous vein graft lesions and reduced left ventricular function (CHF or LVEF under 30%) are each independently associated with a substantially higher risk of future ischemic events after stenting. This reflects their outsized contribution to benefit from prolonged therapy in the original derivation cohort.
The DAPT score is a net risk-benefit tool rather than a pure bleeding-risk score — age is its only bleeding-weighted factor, subtracting points as risk of bleeding complications rises with age. Clinicians often pair it with a dedicated bleeding-risk assessment for a fuller picture.
Yes — because age 75 and older subtracts 2 points and no other risk factors may apply, a patient can score as low as −2. A negative or low score still falls into the 'unfavorable' category, meaning standard-duration therapy is generally preferred over continuing beyond 12 months.
Yes — the DAPT score adds 1 point specifically for a paclitaxel-eluting stent, reflecting device-specific data from the original DAPT Study population. Other drug-eluting stent types used in current practice were not separately weighted in the validated scoring system.
No — this calculator is for informational and educational purposes only and simply reproduces the published DAPT scoring system. Decisions about extending or stopping dual antiplatelet therapy carry real bleeding and clotting risk and must always be made together with your cardiologist, never from this tool alone.
The DAPT score was derived from the DAPT Study (Yeh RW, et al. JAMA. 2016;315(16):1735-1749), a large multicenter randomized trial comparing 12 versus 30 months of dual antiplatelet therapy after coronary stenting, and has since been validated in several other cohorts.
The [GRACE Calculator](/grace-calculator/) estimates in-hospital and 6-month mortality risk at the time of an acute coronary syndrome event, while the DAPT score is applied later, typically around 12 months after stenting, to decide on antiplatelet therapy duration. They address different points in the same patient's cardiac care pathway.
No — the DAPT score focuses specifically on coronary risk factors like prior MI, PCI history, and stent characteristics rather than cerebrovascular history. For stroke-risk assessment in a different clinical context (atrial fibrillation), see the [CHA2DS2-VASc Calculator](/cha2ds2-vasc-calculator/).
Also known as
dual antiplatelet therapy score calculatorDAPT score calculatorprolonged DAPT calculatorstent DAPT duration calculatorpost-PCI antiplatelet therapy score